| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||||
Net Income (Loss) Attributable to Parent | ||||||||||
96,336 | 167,964 | 66,679 | 5,961 | -7,594 | 55,458 | 36,267 | -4,799 | 33,122 | 33,138 | -9,001 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
Depreciation and amortization | ||||||||||
77,895 | 88,988 | 102,796 | 90,524 | 44,632 | 37,197 | 35,966 | 46,368 | 36,306 | 35,767 | 47,229 |
Debt related charges included in interest expense | ||||||||||
7,772 | 49,110 | 10,911 | 7,278 | 11,320 | 773 | 6,366 | 12,557 | 11,389 | 10,680 | - |
Inventory step-up amortization | ||||||||||
- | - | - | - | 22,986 | - | 0 | - | - | - | - |
Stock-based compensation | ||||||||||
9,294 | 10,470 | 14,680 | 8,408 | 9,376 | 13,186 | 14,101 | 10,904 | 12,082 | 6,884 | 5,204 |
Non-cash charges related to customer bankruptcy | ||||||||||
21,695 | 0 | 0 | - | - | - | - | - | - | - | - |
Non-cash lease expense | ||||||||||
7,443 | 0 | 0 | - | - | - | - | - | - | - | - |
Non-cash (gain) loss on equity investments | ||||||||||
-475 | 5,623 | -2,965 | -1,495 | -275 | 4,370 | -694 | -106 | 4,232 | -150 | 0 |
Electrochem litigation gain | ||||||||||
- | - | - | - | - | - | - | - | - | 9,500 | 34,500 |
Electrochem litigation settlement payment | ||||||||||
- | - | - | - | - | - | - | - | - | 25,000 | 0 |
Deferred income taxes | ||||||||||
-10,285 | 61,126 | -59,212 | -7,350 | -10,298 | 531 | -29,856 | 5,733 | 8,776 | 15,419 | -10,120 |
Intangible asset write-down | ||||||||||
- | - | - | - | - | - | - | - | - | - | 15,921 |
Other non-cash gains | ||||||||||
-162 | 148 | 7,110 | 5,216 | 1,093 | -3,214 | 255 | 10,788 | -676 | -743 | 559 |
Gain on sale of discontinued operations | ||||||||||
4,974 | 194,965 | 0 | 0 | - | - | - | - | - | - | - |
Changes in operating assets and liabilities, net of acquisition: | ||||||||||
Accounts receivable | ||||||||||
6,976 | -9,289 | 34,597 | 2,169 | -3,684 | 11,731 | -7,379 | 18,834 | 13,477 | -10,922 | -5,876 |
Inventories | ||||||||||
-3,724 | 16,094 | 986 | -22,170 | 25,752 | 6,726 | 11,508 | 7,481 | 2,139 | -7,406 | -6,898 |
Prepaid expenses and other assets | ||||||||||
31,060 | -8,527 | -4,854 | 3,846 | 1,861 | 3,281 | 353 | -1,253 | 590 | -2,111 | 2,364 |
Accounts payable | ||||||||||
1,887 | -94 | 4,887 | -1,127 | 3,129 | -970 | 1,307 | 5,757 | 4,236 | -7,568 | -12,668 |
Accrued expenses and other liabilities | ||||||||||
-2,744 | -11,756 | 14,977 | -13,935 | -28,605 | 1,214 | -1,176 | 1,459 | 3,678 | -1,472 | -5,050 |
Income taxes payable | ||||||||||
-4,962 | 209 | 14,293 | -7,093 | -9,906 | 2,949 | -2,687 | 1,020 | 1,446 | -2,795 | -4,100 |
Net cash provided by operating activities | ||||||||||
165,358 | 167,299 | 149,357 | 105,532 | 12,479 | 81,276 | 56,755 | 64,831 | 89,921 | 76,885 | 71,766 |
Cash flows from investing activities: | ||||||||||
Proceeds from sale of orthopaedic product lines | ||||||||||
- | - | - | - | - | - | 4,746 | 0 | 0 | - | - |
Acquisition of property, plant and equipment | ||||||||||
48,198 | 44,908 | 47,301 | 58,632 | 44,616 | 24,827 | 18,858 | 41,069 | 22,489 | 16,140 | 19,674 |
Proceeds from sale of property, plant and equipment | ||||||||||
28 | 1,379 | 472 | 347 | 746 | 4 | 300 | - | 212 | 2,537 | 114 |
Purchase of equity investments | ||||||||||
417 | 1,230 | 1,316 | 3,015 | 6,300 | -2,248 | 3,732 | 1,887 | -10,315 | 0 | - |
Proceeds from sale of discontinued operations | ||||||||||
4,734 | 581,429 | 0 | 0 | - | - | - | - | - | - | - |
Proceeds from sale of cost method investments, net | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,050 |
Acquisitions, net | ||||||||||
15,009 | 0 | 0 | - | 423,389 | 16,002 | 0 | 17,224 | 66,493 | 0 | 0 |
Other investing activities | ||||||||||
0 | 0 | -209 | 2,000 | 0 | -2,655 | 740 | -393 | 1,934 | 321 | 531 |
Net cash used in investing activities | ||||||||||
-58,862 | 536,670 | -47,936 | -63,300 | -473,559 | -35,922 | -18,284 | -59,787 | -80,389 | -13,924 | -21,141 |
Cash flows from financing activities: | ||||||||||
Principal payments of long-term debt | ||||||||||
111,500 | 631,469 | 162,558 | 46,000 | 1,232,175 | 10,000 | 458,282 | 32,000 | 40,000 | 78,450 | 46,000 |
Proceeds from senior secured revolving line of credit | ||||||||||
34,000 | 5,000 | 50,000 | - | - | - | - | - | - | - | - |
Payments of senior secured revolving line of credit | ||||||||||
39,000 | 74,000 | 16,000 | - | - | - | - | - | - | - | - |
Proceeds from issuance of long-term debt | ||||||||||
- | - | - | 57,000 | 1,749,750 | 0 | 425,000 | 10,000 | 45,000 | 0 | 12,000 |
Proceeds from the exercise of stock options | ||||||||||
3,242 | 12,409 | 19,324 | 2,821 | 6,583 | - | - | - | - | - | - |
Issuance of common stock | ||||||||||
- | - | - | - | - | 8,278 | 12,807 | 1,263 | 2,401 | 659 | 212 |
Payment of debt issuance and redemption costs | ||||||||||
1,385 | 31,991 | 2,360 | 1,177 | 45,933 | 0 | 2,802 | 0 | 2,213 | 0 | 0 |
Distribution of cash and cash equivalents to Nuvectra Corporation | ||||||||||
- | - | - | 76,256 | 0 | 0 | - | - | - | - | - |
Proceeds from (Payments for) Other Financing Activities | ||||||||||
- | - | - | 2,266 | -440 | -655 | -81 | -717 | -1,500 | -1,030 | -718 |
Purchase of non-controlling interests | ||||||||||
- | - | - | 6,818 | 9,875 | 0 | 0 | - | - | - | - |
Tax withholdings related to net share settlements of restricted stock unit awards | ||||||||||
3,283 | 5,029 | 75 | 3,982 | - | - | - | - | - | - | - |
Net cash provided by (used in) financing activities | ||||||||||
-117,926 | -725,080 | -111,669 | -72,146 | 467,910 | -2,377 | -23,358 | -21,454 | 3,688 | -78,821 | -34,506 |
Effect of foreign currency exchange rates on cash and cash equivalents | ||||||||||
-604 | 2,584 | 2,228 | -448 | -1,176 | -1,618 | 68 | 186 | 405 | 879 | -318 |
Net increase (decrease) in cash and cash equivalents | ||||||||||
-12,034 | -18,527 | -8,020 | -30,362 | 5,654 | 41,359 | 15,181 | -16,224 | 13,625 | -14,981 | 15,801 |